Overcoming Barriers With HIV PrEP

August 16th 2022

Three experts discuss HIV management with PrEP therapies, highlighting the major obstacles that can impact these patients and what can be done to improve their quality of life.

Defining Value With a Changing Biosimilar Landscape

July 29th 2022

Three experts discuss the use of biosimilar and interchangeable biosimilars, exploring how the treatment landscape will change in the upcoming years.

Improving HER2 Biomarker Testing in mCRC

July 11th 2022

A panel of expert medical professionals navigate the evolving landscape in biomarker testing for treating patients with metastatic colorectal cancer.

Managing Mutations in Non-Small Cell Lung Cancer

June 22nd 2022

Three experts discuss advanced non-small cell lung cancer and what it means to have a treat a KRAS G12C mutation.

The Role and Value of Prescription Digital Therapeutics in Behavioral Disorders

June 13th 2022

Two experts, one provider and one payer, shed light on their experiences with prescription digital therapeutics within the behavioral care landscape.

IMiDs in Relapsed/Refractory Multiple Myeloma

June 6th 2022

Two experts discuss the role immunomodulatory drugs (IMiDs) play in the current treatment landscape for relapsed/refractory multiple myeloma and how they can be used effectively.

Mitigating Cardiovascular Risk Through Effective Lipid Management

April 8th 2022

Ian Riddock, MD, and Eliot Brinton, MD, discuss effective use of lipid lowering therapies in patients with atherosclerotic cardiovascular disease (ASCVD).

Cardiovascular Risk and Prostate Cancer Management

December 20th 2021

Shared insight on the role cardiovascular disease management plays in the prostate cancer treatment paradigm.

Optimizing the Transition to Biosimilars: Considerations for Payers

October 26th 2021

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.

Management of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

August 13th 2021

X. Long Zheng, MD, PhD, gives an overview of acquired thrombotic thrombocytopenic purpura and the treatment considerations for the disease.